PHARMACOKINETICS AND TISSUE RESIDUES OF NORFLOXACIN AND ITS N-DESETHYL-METABOLITES AND ORE-METABOLITES IN HEALTHY PIGS

被引:16
作者
ANADON, A
MARTINEZLARRANAGA, MR
DIAZ, MJ
FERNANDEZ, R
MARTINEZ, MA
FERNANDEZ, MC
机构
[1] Institute of Pharmacology and Toxicology, Csic, Department of Toxicology, Faculty of Veterinary Medicine, Universidad Complutense de Madrid, Madrid
关键词
D O I
10.1111/j.1365-2885.1995.tb00582.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetic properties of norfloxacin were determined in healthy pigs after single intramuscular (i.m.) and intravenous (i.v.) dosage of 8 mg/kg body weight. After i.m. and i.v. administration, the plasma concentration-time graph was characteristic of a two-compartment open model. After single i.m. administration, norfloxacin was absorbed rapidly, with a t(max) of 1.46 +/- 0.06 h. The elimination half-life (t(1/2 beta)) and the mean residence time of norfloxacin in plasma were 4.99 +/- 0.28 and 6.05 +/- 0.22 h, respectively, after i.m. administration and 3.65 +/- 0.16 and 3.34 +/- 0.16 h, respectively, after i.v. administration. Intramuscular bioavailability was found to be 53.7 +/- 4.4%. Plasma concentrations greater than 0.2 mu g/mL were achieved at 20 min and persisted up to 8 h post-administration. Maximal plasma concentration was 1.11 +/- 0.03 mu g/mL. statistically significant differences between the two routes of administration were found for the half-lives of both distribution and elimination phases(t(1/2 alpha), t(1/2 beta)) and apparent volume of distribution (V-d(area)). In pigs, norfloxacin was mainly converted to desethylenenorfloxacin and oxonorfloxacin, Considerable tissue concentrations of norfloxacin, desethylenenorfloxacin, and oxonorfloxacin were found when norfloxacin was administered intramuscularly (8 mg/kg on 4 consecutive days). The concentration of the parent fluoroquinolone in liver and kidney ranged between 0.015 and 0.017 mu g/g on day 12 after the end of dosing.
引用
收藏
页码:220 / 225
页数:6
相关论文
共 31 条
  • [1] Adhaml Z.N., Wise R., Weston D., Crump B., The phannacoldnetics and tissue penetration of norfloxacin, Journal of Antimicrobial Chemotherapy, 13, pp. 87-92, (1984)
  • [2] Anadon A., Les Fluoroquinolones: Aspects phannacologiques et toxicologiques, Bulletin de l'Académic Vétérinatre de France, 65, pp. 207-216, (1992)
  • [3] Anadon A., Martinez-Larranaga M.R., Pharmacology and Toxicology of Quinolones, Recent Developments in Therapeutic Drug Monitoring and Clinical Toxicology, pp. 193-198, (1992)
  • [4] Anadon A., Martinez-Larranaga MR., Velez C., Diaz M.J., Bringas P., Pharmacokinetics of norfloxacin and its N‐desethyl‐ and oxo‐metabolites in broiler chickens, American Journal of Veterinary Research, 53, pp. 2084-2089, (1992)
  • [5] Brown S.A., Cooper J., Gauze J.J., Greco S., Weise D.W., Buck J.M., Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administration of the drug, American Journal of Veterinary Research, 51, pp. 1065-1070, (1990)
  • [6] Cozarelli N.R., DNA gyrase and the supercoiling of DNA, Science, 207, pp. 953-960, (1980)
  • [7] Downs J., Andriole V.T., Ryan J.L, In vitro activity of MK‐0366 against clinical urinary pathogens including gentamicin‐resistant Pseudomonas aeruglnosa, Antimicrobial Agents and Chemotherapy, 21, pp. 670-672, (1982)
  • [8] Forchetti C., High‐performance liquid cinematographic procedure for the quantitation of norfloxacin in urine, serum and tissues, Journal of Chromatography, 309, pp. 177-182, (1984)
  • [9] Gellert M., DNA topoisomerases, Annual Reviews of Biochemistry, 50, pp. 879-910, (1981)
  • [10] Gilfillan E.C., Pelak B.A., Bland J.A., Malatesta P.F., Gadebusch H.H., Pharmacokinetic studies of norfloxacin in laboratory animals, Chemotherapy, 30, pp. 288-296, (1984)